Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18 |
Kuppala, Manohar Babu
(Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Syed, Sunayana Begum (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) Bandaru, Srinivas (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) Varre, Sreedevi (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) Akka, Jyothy (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) Mundulru, Hema Prasad (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) |
1 | Volin MV, Koch AE (2011). IL-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res, 31, 745-51. DOI |
2 | Wang Y, Chaudhri G, Jackson RJ, Karupiah G (2009). IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol, 183, 3324-31 DOI |
3 | Wei YS, Lan Y, Liu YG, et al (2007). Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol, 46, 1090-6. DOI |
4 | Yang Y, Qiao J, Li MZ (2010). Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population. Reprod Biol Endocrinol, 8, 125. DOI |
5 | Yao JC, Phan A, Hoff PM, et al (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol, 26, 1316-23. DOI |
6 | Yao L, Setsuda J, Sgadari C, Cherney B, Tosato G (2001). Interleukin-18 expression induced by Epstein-Barr virusinfected cells. J Leukoc Biol, 69, 779-84. |
7 | Yao L, Zhang Y, Chen K, Hu X, Xu LX (2011). Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One, 6, 24684. DOI |
8 | Ye ZB, Ma T, Li H, Jin XL, Xu HM (2007). Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol, 13, 1747-51. DOI |
9 | Yeh WL, Lu DY, Liou HC, Fu WM (2011). A forward loop between glioma and microglia: glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. J Cell Physiol. |
10 | Yoneda S, Umemura T, Katsuyama Y, et al (2011) Association of serum cytokine levels with treatment response to pegylated interferon and ribavirintherapy in genotype 1 chronic hepatitis C patients. J Infect Dis, 203, 1087-95. DOI |
11 | Young-Ik Son, Ramsey MD, Robbie BM, et al (2001). Lotze Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-g Production, and Expansion of Natural Killer Cells1. Cancer Res, 61, 884-8. |
12 | Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD (2010). IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol, 185, 4912-20. DOI |
13 | Zhang Y, Li Y, Ma Y, et al (2011). Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis. Am J Physiol Gastrointest Liver Physiol, 301, 565-73. DOI |
14 | B Zhang, K-F Wu1, Y-M Lin, et al (2004). 1 Gene transfer of pro-IL-18 and IL-1b converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia, 18, 817-25. DOI |
15 | Alagkiozidis I, Facciabene A, Tsiatas M, et al (2011). Timedependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med, 25, 9-77. |
16 | Amin MA, Mansfield PJ, Pakozdi A, et al (2007). IL-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum, 56, 1787-97. DOI |
17 | Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A (2009). Hand neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case-control study. J Laryngol Otol, 123, 444-8. DOI |
18 | Badiola I, Olaso E, Crende O, Friedman SL, Vidal-Vanaclocha F (2011). Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut. |
19 | Bouzgarrou N, Hassen E, Schvoerer E, et al (2008). Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol, 80, 607-14. DOI |
20 | Cao Q, Cai W, Niu G, He L, Chen X (2008). Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res, 14, 6137-45. DOI |
21 | Cao R, Farnebo J, Kurimoto M, Cao Y (1999). IL-18 acts as an angiogenesis and tumor suppressor. FASEB J, 13, 2195-202. DOI |
22 | Carbone A, Vizio B, Novarino A, et al (2009). IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother, 32, 920-31. DOI |
23 | Coughlin CM, Salhany KE, Wysocka M, et al (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest, 101, 1441-52. DOI |
24 | Chattergoon MA, Levine JS, Latanich R, et al (2011). High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis, 204, 1730-40. DOI |
25 | Cho D, Song H, Kim YM, et al (2000). Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 60, 2703-9. |
26 | Cho ML, Jung YO, Moon YM, et al (2006). IL-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 103, 159-66. DOI |
27 | Cui G, Yuan A, Goll R, et al (2007). Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother, 56, 1993-2001. DOI |
28 | Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A (2006). Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol, 28, 319-22. |
29 | Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY (2005). Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 17, 51-5. |
30 | Elaraj DM, Weinreich DM, Varghese S, et al (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res, 12, 1088-96. DOI |
31 | Elias AS, et al. 2009, PD-1 Induced IL10 Production by Monocytes Impairs T-cell Activation in a Reversible Fashion. Nature Medicine, 452-9. |
32 | Gollob JA, Mier JW, Veenstra K, et al (2000). Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res, 6, 1678-92. |
33 | Farhat K, Hassen E, Bouzgarrou N, et al (2008). Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 43, 132-7. DOI ScienceOn |
34 | Farjadfar A, Mojtahedi Z, Ghayumi MA, et al (2009). Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol, 48, 971-6. DOI ScienceOn |
35 | Fujita K, Ewing CM, Isaacs WB, Pavlovich CP (2011). Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer, 129, 424-32. DOI |
36 | Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A (2009). IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol, 24, 1119-22. DOI |
37 | Han Ming-yong, Zheng Shu, Yu Jin-ming, et al (2004). Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ SCI, 5, 472-6. DOI |
38 | Ingram JT, Yi JS, Zajac AJ (2011). Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog, 7, 1002273. DOI |
39 | Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L (2005). VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine, 30, 93-9. DOI |
40 | Jebreel A, Mistry D, Loke D, et al (2007). Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol, 121, 246-52. |
41 | Jung MK, Park Y, Song SB, et al (2011). Erythroid differentiation regulator 1, an interleukin 18-regulated gene, acts as a metastasis suppressor in melanoma. J Invest Dermatol, 131, 2096-104. DOI |
42 | Kang JS, Bae SY, Kim HR, et al (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 30, 1987-96. DOI |
43 | Kaser A, Novick D, Rubinstein M, et al (2002). Tilg interferon-a induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol, 129, 332-8 DOI |
44 | Kei-ichi Y, Rachael C, Rebecca D, et al (2006). Kupper1 Expression of Interleukin-18 and Caspase-1in Cutaneous T-Cell Lymphoma. Clin Cancer Res, 12, 2. |
45 | Khalili-Azad T, Razmkhah M, Ghiam AF, et al (2009). Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma, 56, 22-5. DOI |
46 | Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ (2009). Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 15, 2323-34. DOI |
47 | Kim J, Kim C, Kim TS, et al (2006). IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun, 344, 1284-9. DOI |
48 | Kim J, Shao Y, Kim SY, et al (2008). Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell, 19, 433-44. |
49 | Kim KE, Song H, Kim TS, et al (2007). IL-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene, 26, 1468-76. DOI |
50 | Kim KE, Song H, Hahm C, et al (2009). Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J Immunol, 182, 3548-55. DOI |
51 | Kim YS, Cheong JY, Cho SW, et al (2009). A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci, 54, 2722-8. DOI |
52 | Kinoshita M, Miyazaki H, Ono S, et al (2011). Enhancement of neutrophil function by interleukin-18 therapy protects burn-injured mice from methicillin-resistant Staphylococcus aureus. Infect Immun, 79, 2670-80. DOI |
53 | Kuryliszyn-Moskal A, Dubicki A, Zarzycki W, Zonnenberg A, Gorska M (2011). Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sEselectin levels in patients with type 1 diabetes complicated by microangiopathy. Folia Histochem Cytobiol, 49, 104-10. DOI |
54 | Ledee N, Petitbarat M, Rahmati M, et al (2011). New preconception immune biomarkers for clinical practice: interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on the follicular side. J Reprod Immunol, 88, 118-23. DOI |
55 | Li W, Kubo S, Okuda A, et al (2010). Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother, 33, 287-96. DOI |
56 | Lissoni P, Brivio F, Rovelli F, et al (2000). Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents, 14, 275-7. |
57 | Michael JR, John MK, Theodore FL, et al (2010). Dar4 A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer. Clin Cancer Res, 14, 11. |
58 | Liu Y, Lin N, Huang L, Xu Q, Pang G (2007). Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 26, 613-8. DOI |
59 | Majima T, Ichikura T, Chochi K, et al (2006). Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer, 118, 388-95. DOI |
60 | Majima T, Ichikura T, Seki S, et al (2002). The influence of interleukin-10 and interleukin-18 on interferon-gamma production by peritoneal exudate cells in patients with gastric carcinoma. Anticancer Res, 22, 1193-9. |
61 | Mohran ZY, Ali-Eldin FA, Abdel Aal HA (2011). Serum interleukin-18: does it have a role in the diagnosis of hepatitis C virus related hepatocellular carcinoma? Arab J Gastroenterol, 12, 29-33. DOI |
62 | Mojtahedi Z, Khademi B, Hashemi SB, et al (2011). Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res, 17, 7-10. DOI |
63 | Muller J, Feige K, Wunderlin P, et al (2011). Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother, 34, 58-64. DOI |
64 | Nilkaeo A, Bhuvanath S (2006). Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediators Inflamm, 3, 67120. |
65 | Nishio S, Yamada N, Ohyama H, et al (2008). Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alphagalactosylceramide and interleukin-18. Cancer Sci, 99, 113-20. |
66 | Page F, Galon J, Galina K, et al (2005). Wolf-Herman Fridman, and Berthold Henglein Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 105, 1632-9. DOI |
67 | Nong LG, Luo B, Zhang L, Nong HB (2009). Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol, 28, 507-13. DOI ScienceOn |
68 | Okamoto M, Azuma K, Hoshino T, et al (2009). Correlation of decreased survival and IL-18 in bone metastasis. Intern Med, 48, 763-73. DOI |
69 | Orengo AM, Fabbi M, Miglietta L, et al (2010). Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J Cancer. |
70 | Park CC, Morel JC, Amin MA, et al (2001). Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 167, 1644-53. DOI |
71 | Park S, Cheon S, Cho D (2007). The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 4, 329-35. |
72 | Qiao H, Sonoda KH, Ikeda Y, et al (2007). IL-18 regulates pathological intraocular neovascularization. J Leukoc Biol, 81, 1012-21. DOI |
73 | Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003). Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg, 38, 301-7. DOI |
74 | Robertson MJ, Mier JW, Logan T, et al (2006). Clinical and biological effects of recombinant humaninterleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res, 12, 4265-73. DOI |
75 | Rovina N, Hillas G, Dima E, et al (2011). VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 54, 277-81. DOI ScienceOn |
76 | Salcedo R, Worschech A, Cardone M, et al (2010).MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med, 207, 1625-36. DOI |
77 | Sabel MS, Su G, Griffith KA, Chang AE (2010). Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat, 122, 325-36. DOI |
78 | Saenz-Lopez P, Carretero R, Vazquez F, et al (2010). Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol, 71, 309-13. DOI |
79 | Salado C, Olaso E, Gallot N, et al (2011). Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl, 9, 59. DOI |
80 | Samsami DA, Shahriary K, Kashef MA, et al (2009). Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep, 36, 2393-7. DOI |
81 | Setsuda J, Teruya-Feldstein J, Harris NL, et al (1999). Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol, 155, 257-65. DOI |
82 | Skopiński P, Rogala E, Duda-Krol B, et al (2005). Increased IL-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J Diabetes Complications, 19, 335-8. DOI |
83 | Sobti RC, Shekari M, Tamandani DM, Malekzadeh K, Suri V (2008). Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. Oncol Res, 17, 159-66. DOI |
84 | Tasaki K, Yoshida Y, Maeda T, et al (2000). Protective immunity is induced in murine colon carcinoma cells by the expression of IL-12 orIL-18, which activate type 1 helper T cells. Cancer Gene Ther, 7, 247-54. DOI |
85 | Song H, Kim J, Lee HK, et al (2011). Selenium inhibits migration of murine melanoma cells via down-modulation of IL-18 expression. Int Immunopharmacol. |
86 | Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Muminovic Z, Cickusic E (2011). Interleukin 18 expression in the primary breast cancer tumour tissue. Med Glas Ljek komore Zenicko-doboj kantona, 8, 109-15. |
87 | Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y (2007). Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol, 13, 4345-9. DOI |
88 | Terme M, Ullrich E, Aymeric L, et al (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res, 71, 5393-9. DOI |
89 | Thong-Ngam D, Tangkijvanich P, Lerknimitr R, et al (2006). Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol, 12, 4473-7. DOI |
90 | Tsuboi K, Miyazaki T, Nakajima M, et al (2004). Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett, 205, 207-14. DOI |
91 | Tsurumi H, Kasahara S, Kanemura N, et al (2011). Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol, 87, 217-27. DOI |
92 | Vairaktaris E, Serefoglou ZC, Yapijakis C, et al (2007). The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res, 27, 4011-4. |